Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma☆

已完结 100 由医休发布于 2026/6/18 0:11:57

DOI:10.1016/j.annonc.2025.08.008
作者：A. Arance , M.-A. Berciano-Guerrero , J. Guo , M.S. Carlino , P.A. Ascierto , M. Burotto , L. Mortier , P. Queirolo , V. Chiarion-Sileni , J. Schachter ,&n
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1016/j.annonc.2025.08.008

Elsevier

Abstract：BackgroundLenvatinib plus pembrolizumab demonstrated antitumor activity in advanced melanoma after prior anti-programmed cell death protein or ligand 1 [PD-(L)1] therapy in LEAP-004. Here, w

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:SpringerA robust protocol for site-directed mutagenesis of the D1 protein inChlamydomonas reinhardtii: A PCR-splicedpsbA gene in a plasmid conferring spectinomycin resistance was introduced into apsbA deletion strain.